Anemia in Non-Dialysis-Dependent CKD Patients Characterized
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
Kidney Week 2016
Novel Drug Shows Promise for FSGS
Sparsentan could become the first FDA-approved medication for the focal segmental glomerularsclerosis.
Bone Mass Increases After Total Parathyroidectomy
In a study, 94.1% of total PTx patients had improvement of bone mineral density at their most affected site.
Optimal Vitamin C Dose for Anemia in Hemodialysis Patients Unclear
Pending future research, patients should avoid taking more than 120 mg per day.
Parathyroidectomy Offers Survival Advantage
Surgery decreased the risk of death from any cause by 32% compared with usual treatment.
Parathyroidectomy Rarely Achieves KDIGO Targets
Just 6.7% of patients had target levels of calcium, phosphorus, and parathyroid hormone a year after surgery.
Novel Hyperkalemia Drug Has No Significant BP Effects Long-Term
Sodium zirconium cyclosilicate treatment for 12 months had no clinically meaningful effects on systolic or diastolic pressure, study finds.
Dialysis Patient Age May Affect Hyperphosphatemia Management
Younger patients are less likely to respond to treatment with sucroferric oxyhydroxide or sevelamer.
Phosphate Enemas Can Cause Hyperphosphatemia
Purgative products introduce 10 times the normal daily amount of phosphorus into the body.
More Intensive Education on Diet, Binders Needed
Educated patients achieved better phosphate binder adherence.
Next post in Kidney Week 2016
